Ian joined Brandon Capital in 2017.
Before joining Brandon Capital Ian was as an independent medicinal chemistry consultant working with a range of Australian and international Venture Capital, Biotech and Academic organisations. During this time, he co-founded MycRx. Prior to this, Ian was Head of Chemistry at the Cancer Therapeutics CRC, Melbourne where he co-led the project team that developed Narmafotinib. Prior to moving to Australia, Ian worked for 10 years as a Medicinal Chemist and Project Leader with GlaxoSmithKline, UK and as a Senior Synthetic Chemist with Zeneca, UK.
Ian co-founded MycRx and Foray Therapeutics. He also currently advises Amplificare, Azura Ophthalmics, Axelia Oncology, Certa Therapeutics, Ena Respiratory and Que Oncology.
Ian has a Bachelor of Science (Honours) and a PhD in Synthetic Organic Chemistry from the University of Nottingham, UK. He carried out postdoctoral research at the Universities of South Paris, France and Sheffield, UK. Ian is a Chartered Chemist (CChem) and Fellow of the Royal Society of Chemistry (FRSC).
